HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dave Francisco Selected Research

Collagen

2/2014Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-β1 in airway fibroblasts in asthma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dave Francisco Research Topics

Disease

8Asthma (Bronchial Asthma)
01/2022 - 01/2012
3Inflammation (Inflammations)
01/2022 - 01/2012
2Eosinophilia
01/2018 - 03/2016
2Airway Remodeling
01/2016 - 02/2014
1COVID-19
07/2020
1Respiratory Tract Diseases (Respiratory Tract Disease)
08/2014
1Infections
04/2012
1Overweight
01/2012
1Obesity
01/2012

Drug/Important Bio-Agent (IBA)

5Interleukin-13IBA
01/2022 - 02/2014
3CytokinesIBA
01/2020 - 01/2012
2Proteins (Proteins, Gene)FDA Link
01/2022 - 04/2012
2MucinsIBA
01/2022 - 01/2020
2Pulmonary Surfactant-Associated Protein A (Surfactant Protein A)IBA
01/2020 - 08/2014
2Matrix Metalloproteinases (MMPs)IBA
01/2016 - 02/2014
1CarbohydratesIBA
01/2022
1Peptides (Polypeptides)IBA
01/2022
1Angiotensin-Converting Enzyme 2IBA
07/2020
1Serine Proteases (Serine Protease)IBA
07/2020
1AllergensIBA
01/2018
1Surface-Active Agents (Surfactants)IBA
03/2016
1ElastinIBA
01/2016
1Methacholine Chloride (Methacholine)FDA Link
01/2016
1NucleotidesIBA
08/2014
1Transforming Growth Factors (Transforming Growth Factor)IBA
02/2014
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
02/2014
1CollagenIBA
02/2014
1InterleukinsIBA
02/2014
1Protein Tyrosine PhosphatasesIBA
04/2012
1Interleukin-8 (Interleukin 8)IBA
04/2012
1LeptinIBA
01/2012
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2012

Therapy/Procedure

1Therapeutics
01/2018